Neurosense Therapeutics Ltd Stock Market Value
| NRSNW Stock | USD 0.15 0.11 42.31% |
| Symbol | NeuroSense |
NeuroSense Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeuroSense Therapeutics. If investors know NeuroSense will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeuroSense Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.94) | Return On Assets (1.51) | Return On Equity (4.95) |
The market value of NeuroSense Therapeutics is measured differently than its book value, which is the value of NeuroSense that is recorded on the company's balance sheet. Investors also form their own opinion of NeuroSense Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is NeuroSense Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeuroSense Therapeutics' market value can be influenced by many factors that don't directly affect NeuroSense Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeuroSense Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeuroSense Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeuroSense Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
NeuroSense Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to NeuroSense Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of NeuroSense Therapeutics.
| 05/30/2024 |
| 11/26/2024 |
If you would invest 0.00 in NeuroSense Therapeutics on May 30, 2024 and sell it all today you would earn a total of 0.00 from holding NeuroSense Therapeutics Ltd or generate 0.0% return on investment in NeuroSense Therapeutics over 180 days. NeuroSense Therapeutics is related to or competes with Eliem Therapeutics, Scpharmaceuticals, Milestone Pharmaceuticals, Seres Therapeutics, and Lumos Pharma. NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments f... More
NeuroSense Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure NeuroSense Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess NeuroSense Therapeutics Ltd upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 25.17 | |||
| Information Ratio | 0.0776 | |||
| Maximum Drawdown | 126.67 | |||
| Value At Risk | (40.00) | |||
| Potential Upside | 41.67 |
NeuroSense Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for NeuroSense Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as NeuroSense Therapeutics' standard deviation. In reality, there are many statistical measures that can use NeuroSense Therapeutics historical prices to predict the future NeuroSense Therapeutics' volatility.| Risk Adjusted Performance | 0.0737 | |||
| Jensen Alpha | 1.72 | |||
| Total Risk Alpha | (1.50) | |||
| Sortino Ratio | 0.0643 | |||
| Treynor Ratio | 10.05 |
NeuroSense Therapeutics Backtested Returns
NeuroSense Therapeutics is out of control given 3 months investment horizon. NeuroSense Therapeutics has Sharpe Ratio of 0.24, which conveys that the firm had a 0.24% return per unit of risk over the last 3 months. We were able to interpolate twenty-seven different technical indicators, which can help you to evaluate if expected returns of 62.6% are justified by taking the suggested risk. Use NeuroSense Therapeutics Risk Adjusted Performance of 0.0737, downside deviation of 25.17, and Mean Deviation of 13.31 to evaluate company specific risk that cannot be diversified away. NeuroSense Therapeutics holds a performance score of 19 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of 0.17, which conveys not very significant fluctuations relative to the market. As returns on the market increase, NeuroSense Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding NeuroSense Therapeutics is expected to be smaller as well. Use NeuroSense Therapeutics sortino ratio, semi variance, as well as the relationship between the Semi Variance and day median price , to analyze future returns on NeuroSense Therapeutics.
Auto-correlation | -0.03 |
Very weak reverse predictability
NeuroSense Therapeutics Ltd has very weak reverse predictability. Overlapping area represents the amount of predictability between NeuroSense Therapeutics time series from 30th of May 2024 to 28th of August 2024 and 28th of August 2024 to 26th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of NeuroSense Therapeutics price movement. The serial correlation of -0.03 indicates that only 3.0% of current NeuroSense Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.03 | |
| Spearman Rank Test | -0.19 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
NeuroSense Therapeutics lagged returns against current returns
Autocorrelation, which is NeuroSense Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting NeuroSense Therapeutics' stock expected returns. We can calculate the autocorrelation of NeuroSense Therapeutics returns to help us make a trade decision. For example, suppose you find that NeuroSense Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
NeuroSense Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If NeuroSense Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if NeuroSense Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in NeuroSense Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
NeuroSense Therapeutics Lagged Returns
When evaluating NeuroSense Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of NeuroSense Therapeutics stock have on its future price. NeuroSense Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, NeuroSense Therapeutics autocorrelation shows the relationship between NeuroSense Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in NeuroSense Therapeutics Ltd.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for NeuroSense Stock Analysis
When running NeuroSense Therapeutics' price analysis, check to measure NeuroSense Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuroSense Therapeutics is operating at the current time. Most of NeuroSense Therapeutics' value examination focuses on studying past and present price action to predict the probability of NeuroSense Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuroSense Therapeutics' price. Additionally, you may evaluate how the addition of NeuroSense Therapeutics to your portfolios can decrease your overall portfolio volatility.